Probiotix Health

Probiotix Health EBITDA per Share

The EBITDA per Share of Probiotix Health (PBX.AQ) as of Nov 3, 2026 is -0.01 GBP. In the previous year, EBITDA per Share was -0.01 GBP — a change of 5.53% (lower).

EBITDA per Share

-0.01GBP

YoY

5.53%

Last updated:

EBITDA per Share of Probiotix Health is 2024 -0.01 GBP. EBITDA per Share of Probiotix Health was 2023 -0.01 GBP. It decreases by 5.53% lower compared to the previous year.

The Probiotix Health EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
-0.00 GBP
Jan 1, 2020
0.00 GBP
Jan 1, 2021
0.00 GBP
Jan 1, 2022
-0.00 GBP
Jan 1, 2023
-0.01 GBP
Jan 1, 2024
-0.01 GBP
The Probiotix Health EBITDA per Share history
YEAREBITDA per ShareYoY
-0.01GBP+5.53%
-0.01GBP+568.70%
-0.00GBP-143.93%
0.00GBP+157.91%
0.00GBP-120.19%
-0.00GBP—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Probiotix Health Stock analysis

What does Probiotix Health do? ProBiotix Health PLC develops probiotics to tackle cardiovascular disease and lifestyle conditions, focusing on cholesterol reduction through its LP-LDL ingredient. The company commercializes LP-LDL as an ingredient and in CholBiome products, including CholBiome, CholBiome X3, CholBiome BP, and CholBiome VH, which improve blood lipid profiles and blood pressure. ProBiotix leverages its OptiScreen and OptiBiotic platform technologies to identify metabolic pathways for potential health benefits across various diseases. The firm targets healthcare providers, supplement manufacturers, and consumers seeking natural solutions for cardiovascular health. ProBiotix Health PLC's revenue streams include selling LP-LDL as an ingredient to manufacturers and direct sales of CholBiome products under white-label and own-label arrangements. The CholBiome range serves segments such as cardiovascular health management, lifestyle disease prevention, and natural health supplements. The company's pipeline, driven by OptiScreen and OptiBiotic, supports future product development in metabolic health and disease-specific applications. The firm's business model centers on developing and commercializing probiotic solutions for cardiovascular health, with LP-LDL as the core product. CholBiome products are positioned for consumers and healthcare partners, while the OptiScreen and OptiBiotic platforms enable expansion into new therapeutic areas. ProBiotix's revenue comes from ingredient sales and branded product lines targeting health-conscious individuals and industry partners in the probiotic and supplement markets. Probiotix Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Probiotix Health stock

EBITDA per Share of Probiotix Health is -0.01 GBP in 2024.

EBITDA per Share of Probiotix Health changed from -0.01 GBP to -0.01 GBP, representing a 5.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Probiotix Health since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Probiotix Health

All Key Metrics — Probiotix Health